PADMANEE SHARMA to Mutation
This is a "connection" page, showing publications PADMANEE SHARMA has written about Mutation.
Connection Strength
0.261
-
Loss of ARID1A 'loops' in STING. Trends Immunol. 2024 Aug; 45(8):568-570.
Score: 0.058
-
ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC. Sci Transl Med. 2020 06 17; 12(548).
Score: 0.043
-
Nivolumab in Patients with Advanced Platinum-resistant Urothelial Carcinoma: Efficacy, Safety, and Biomarker Analyses with Extended Follow-up from CheckMate 275. Clin Cancer Res. 2020 10 01; 26(19):5120-5128.
Score: 0.043
-
Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov. 2015 Aug; 5(8):860-77.
Score: 0.031
-
Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 2015 Apr 09; 161(2):205-14.
Score: 0.030
-
Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma. Nat Commun. 2020 04 15; 11(1):1839.
Score: 0.011
-
Comprehensive T cell repertoire characterization of non-small cell lung cancer. Nat Commun. 2020 01 30; 11(1):603.
Score: 0.011
-
Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer. Eur Urol. 2019 11; 76(5):599-603.
Score: 0.010
-
TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. Cancer Discov. 2017 10; 7(10):1088-1097.
Score: 0.009
-
Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med. 2017 03 01; 9(379).
Score: 0.009
-
State of the science: an update on renal cell carcinoma. Mol Cancer Res. 2012 Jul; 10(7):859-80.
Score: 0.006